Document is current
Any future updates will be listed below
-
Authors
Melica, Giovanna
Preston, Elaina
Palazzo, Meighan
Seier, Kenneth
Malard, Florent
Cho, Christina https://orcid.org/0000-0002-7964-3011
Devlin, Sean M.
Maloy, Molly
Borrill, Taylor
Maslak, Peter
Shah, Gunjan L. https://orcid.org/0000-0002-9977-0456
Perales, Miguel-Angel https://orcid.org/0000-0002-5910-4571
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | NIH Clinical Center (P30CA008748)
- License Information
-
More Information
Article History
Received: 26 October 2023
Revised: 16 January 2024
Accepted: 26 January 2024
First Online: 13 February 2024
Competing interests
: MAP: honoraria from Adicet, Allogene, Allovir, Caribou Biosciences, Celgene, Bristol-Myers Squibb, Equilium, Exevir, ImmPACT Bio, Incyte, Karyopharm, Kite/Gilead, Merck, Miltenyi Biotec, MorphoSys, Nektar Therapeutics, Novartis, Omeros, OrcaBio, Syncopation, VectivBio AG, and Vor Biopharma. He serves on DSMBs for Cidara Therapeutics, Medigene, and Sellas Life Sciences, and the scientific advisory board of NexImmune. He has ownership interests in NexImmune, Omeros and OrcaBio. He has received institutional research support for clinical trials from Allogene, Incyte, Kite/Gilead, Miltenyi Biotec, Nektar Therapeutics, and Novartis. GM: honoraria and institutional research support from Gilead, Janssen and MSD. GLS: Research funding from Janssen, Amgen, Beyond Spring, GPCR, and BMS. DSMB for ArcellX. No financial disclosure were reported by any other authors.
